3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, phase 2 clinical trial.
Michael C Mithoefer, Ann T Mithoefer, Allison A. Feduccia, Lisa Jerome, Mark T Wagner, Joy Wymer, Julie Holland, Scott Hamilton, Berra Yazar-Klosinski, Amy Emerson, Rick Doblin
Lancet Psychiatry May 1, 2018 DOI: 10.1016/s2215-0366(18)30135-4 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Randomized, double-blind, dose-response, phase 2 clinical trial Peer reviewed |
|---|---|
| Population | Military veterans, firefighters, and police officers with post-traumatic stress disorder |
| Topics | MDMA Psychedelic-assisted therapy PTSD |
| Keywords | This condition PTSD Symptoms Profound trauma Significant relief Promising treatment option MDMA-Assisted Psychotherapy MDMA Innovative therapeutic approach Investigated Participants Randomly assigned Findings revealed First responders Firefighters Police officers |
| Citations | 443 |
| Key findings | The active dose of MDMA-assisted psychotherapy led to significant and lasting reductions in PTSD symptoms compared to a lower dose. |
Abstract
3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, phase 2 clinical trial.